{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:36Z","timestamp":1791928956864,"version":"4.3.4"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.yebeh.2024.110123","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T13:38:43Z","timestamp":1730468323000},"page":"110123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Evolving treatment strategies for early-life seizures in Tuberous Sclerosis Complex: A review and treatment algorithm"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5154-8717","authenticated-orcid":false,"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.110123_b0005","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.3928\/19382359-20170320-01","article-title":"Tuberous sclerosis complex: a review","volume":"46","author":"Randle","year":"2017","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.yebeh.2024.110123_b0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0072-9752(07)87009-6","article-title":"Tuberous sclerosis","volume":"87","author":"Curatolo","year":"2008","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0015","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.06.012","article-title":"Epilepsy is heterogeneous in early-life tuberous sclerosis complex","volume":"123","author":"Ihnen","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/epi4.12286","article-title":"Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study","volume":"4","author":"Nabbout","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.110123_b0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yebeh.2017.02.007","article-title":"Influence of seizures on early development in tuberous sclerosis complex","volume":"70","author":"Capal","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/s-0041-1727142","article-title":"TSC1 and TSC2: tuberous sclerosis complex and its related epilepsy phenotype","volume":"21","author":"Di Napoli","year":"2023","journal-title":"J Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/08830738050200101301","article-title":"Prognostic significance of tuber count and location in tuberous sclerosis complex","volume":"20","author":"Doherty","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2021.12.012","article-title":"Tuber brain proportion determines epilepsy onset in children with tuberous sclerosis complex","volume":"129","author":"Zhang","year":"2022","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.26015","article-title":"Tuber locations associated with infantile spasms map to a common brain network","volume":"89","author":"Cohen","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0055","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/epi.13050","article-title":"Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs","volume":"56","author":"Overwater","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.seizure.2017.10.005","article-title":"Epilepsy in tuberous sclerosis patients in Sweden - Healthcare utilization, treatment, morbidity, and mortality using national register data","volume":"53","author":"Welin","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.110123_b0065","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/17512433.2021.1911643","article-title":"Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature","volume":"14","author":"Strzelczyk","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2024.110123_b0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/epi4.12666","article-title":"Medical treatment in infants and young children with epilepsy: off-label use of antiseizure MEDICATIONS. SURVEY REPORT of ILAE task force medical therapies in children","volume":"8","author":"Sourbron","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.110123_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106348","article-title":"Long-term outcomes of ketogenic diet in patients with tuberous sclerosis complex-derived epilepsy","volume":"164","author":"Youn","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110123_b0080","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/brain\/awz411","article-title":"Resective epilepsy surgery in tuberous sclerosis complex: a nationwide multicentre retrospective study from China","volume":"143","author":"Liu","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2024.110123_b0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2024.110123_b0090","doi-asserted-by":"crossref","first-page":"e1217","DOI":"10.1212\/WNL.0000000000012511","article-title":"Comparative effectiveness of initial treatment for infantile spasms in a contemporary US cohort","volume":"97","author":"Grinspan","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110123_b0095","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110123_b0100","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1528-1157.1996.tb00627.x","article-title":"Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups","volume":"37","author":"Aicardi","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2024.110123_b0105","first-page":"S52","article-title":"Therapeutic trial of vigabatrin in refractory infantile spasms","author":"Chiron","year":"1991","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eplepsyres.2013.05.003","article-title":"Epileptic spasms in tuberous sclerosis complex","volume":"106","author":"Hsieh","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110123_b0115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14737175.2023.2216385","article-title":"Efficacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: a systematic review","volume":"23","author":"Prezioso","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2024.110123_b0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/088307389901400201","article-title":"Topical review: vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review","volume":"14","author":"Hancock","year":"1999","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110123_b0130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.yebeh.2016.03.030","article-title":"Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry","volume":"60","author":"Pellock","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2018.09.016","article-title":"High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex","volume":"148","author":"Hussain","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110123_b0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5603\/PJNNS.a2021.0063","article-title":"Vigabatrin - new data on indications and safety in paediatric epilepsy","volume":"55","author":"Golec","year":"2021","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.yebeh.2024.110123_b0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40272-019-00376-0","article-title":"Update on drug management of refractory epilepsy in tuberous sclerosis complex","volume":"22","author":"van der Poest","year":"2020","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.yebeh.2024.110123_b0150","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0883073812446485","article-title":"Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures","volume":"28","author":"Yum","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0155","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1528-1167.2008.01589.x","article-title":"Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile","volume":"49","author":"Camposano","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0160","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yebeh.2012.12.033","article-title":"Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex","volume":"27","author":"Friedman","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0883073818768309","article-title":"Vigabatrin for epileptic spasms and tonic seizures in tuberous sclerosis complex","volume":"33","author":"van der Poest Clement","year":"2018","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/08830738211048326","article-title":"Focal epilepsy in children with tuberous sclerosis complex: does vigabatrin control focal seizures?","volume":"37","author":"Lin","year":"2022","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0175","unstructured":"TSC Alliance. FDA Approves Sabril Label Expansion For Patients 2 To 10 Years Old. In."},{"key":"10.1016\/j.yebeh.2024.110123_b0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2020.11.003","article-title":"Approach to preventive epilepsy treatment in tuberous sclerosis complex and current clinical practice in 23 countries","volume":"115","author":"S\u0142owi\u0144ska","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0185","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/epi.16379","article-title":"Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study","volume":"60","author":"Wu","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107908","article-title":"Modifying genetic epilepsies - Results from studies on tuberous sclerosis complex","volume":"166","author":"Jozwiak","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2024.110123_b0195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.07.008","article-title":"Preventive antiepileptic treatment in tuberous sclerosis complex: a long-term","volume":"101","author":"Jozwiak","year":"2019","journal-title":"Prospective Trial Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0210","article-title":"Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial","author":"Bebin","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0215","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1042\/CS20150149","article-title":"Cellular and molecular effects of the mTOR inhibitor everolimus","volume":"129","author":"Saran","year":"2015","journal-title":"Clin Sci"},{"key":"10.1016\/j.yebeh.2024.110123_b0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2024.110123_b0225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.phrs.2016.03.039","article-title":"mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis","volume":"107","author":"Citraro","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.yebeh.2024.110123_b0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0235","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211031100","article-title":"Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine","volume":"14","author":"Schubert-Bast","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2024.110123_b0240","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2024.110123_b0245","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.yebeh.2024.110123_b0250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0255","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/epi.17099","article-title":"Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3","volume":"62","author":"Franz","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0260","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","article-title":"Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial","volume":"8","author":"Franz","year":"2018","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.yebeh.2024.110123_b0265","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110123_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107182","article-title":"Developmental outcomes in children\/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus","volume":"111","author":"Kadish","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.seizure.2022.10.022","article-title":"EEG-Findings during long-term treatment with everolimus in TSC-associated and therapy-resistant epilepsies in children","volume":"103","author":"Wiegand","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.110123_b0280","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders","volume":"4","author":"Krueger","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0285","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40120-023-00476-7","article-title":"Effect of mTOR inhibitors in epilepsy treatment in children with tuberous sclerosis complex under 2 years of age","volume":"12","author":"\u015amia\u0142ek","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2024.110123_b0290","unstructured":"Svarrer EMM, Fischer CM, Frederiksen MG, Born AP, Hoei-Hansen CE. Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children. Dan Med J 2019;66."},{"key":"10.1016\/j.yebeh.2024.110123_b0295","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-016-0530-z","article-title":"Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study","volume":"11","author":"Samueli","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2024.110123_b0305","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13023-019-1077-6","article-title":"Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study","volume":"14","author":"Saffari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2024.110123_b0310","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1111\/epi.14529","article-title":"Everolimus in infants with tuberous sclerosis complex-related West syndrome: First results from a single-center prospective observational study","volume":"59","author":"Samueli","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2024.110123_bib646","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ejpn.2018.06.007","article-title":"TSCure Research Group. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience","volume":"22","author":"Krueger","year":"2018","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1016\/j.yebeh.2024.110123_b0315","first-page":"151","article-title":"Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized","volume":"172","author":"J\u00f3\u017awiak","year":"2016","journal-title":"Controlled Clinical Trial J Pediatr"},{"key":"10.1016\/j.yebeh.2024.110123_b0320","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2020.03.018","article-title":"Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study","volume":"79","author":"He","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.110123_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.704978","article-title":"Antiepileptic effect and safety profile of rapamycin in pediatric patients with tuberous sclerosis complex","volume":"13","author":"Sadowski","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0330","first-page":"19","article-title":"The efficacy and safety of rapamycin in children with tuberous sclerosis: a cross-sectional study","volume":"17","author":"Tehrani","year":"2023","journal-title":"Iran J Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0335","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.0000000000003077","article-title":"Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial","volume":"87","author":"Overwater","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110123_b0340","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2022.03.003","article-title":"Sirolimus treatment for tuberous sclerosis complex prior to epilepsy: Evidence from a registry-based real-world study","volume":"97","author":"Shen","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.110123_b0345","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010365","article-title":"Safety of sirolimus in patients with tuberous sclerosis complex under two years of age-a bicenter retrospective study","volume":"12","author":"\u015amia\u0142ek","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.yebeh.2024.110123_b0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.03.014","article-title":"Cannabidiol: A review of clinical efficacy and safety in epilepsy","volume":"96","author":"Samanta","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108577","article-title":"A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development","volume":"128","author":"Samanta","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0360","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jocn.2020.05.030","article-title":"The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex","volume":"77","author":"Barnett","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.yebeh.2024.110123_b0365","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0370","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/epi.17199","article-title":"Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6","volume":"63","author":"Wu","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0375","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106263","article-title":"Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam","volume":"160","author":"Savage","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.110123_b0385","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pediatrneurol.2023.10.012","article-title":"Real-Life experience with purified cannabidiol treatment for refractory epilepsy: a multicenter retrospective study","volume":"150","author":"Tzadok","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106988","article-title":"Cannabidiol in treatment of refractory epileptic spasms: An open-label study","volume":"106","author":"Herlopian","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0395","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/epi.17150","article-title":"Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial","volume":"63","author":"Thiele","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0400","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.13013","article-title":"Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program","author":"Weinstock","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.110123_b0405","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/epi.16936","article-title":"The long-term efficacy of cannabidiol in the treatment of refractory epilepsy","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0410","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18069","article-title":"Have epilepsy outcomes changed for children with tuberous sclerosis complex in Queensland, Australia?","author":"Braun","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0415","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0420","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/epi.17454","article-title":"Clinical seizure semiology is subtle and identification of seizures by parents is unreliable in infants with tuberous sclerosis complex","volume":"64","author":"Lynch","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2024.05.010","article-title":"Early subclinical status epilepticus may contribute to developmental delays in infants with tuberous sclerosis complex","volume":"157","author":"Melendez-Zaidi","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpn.2023.08.005","article-title":"Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy","volume":"47","author":"Specchio","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107624","article-title":"Potential induction of epileptic spasms by nonselective voltage-gated sodium channel blockade: Interaction with etiology","volume":"115","author":"Hussain","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114286","article-title":"Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam","volume":"360","author":"Rana","year":"2023","journal-title":"Exp Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110067","article-title":"Neuromodulation strategies in developmental and epileptic encephalopathies","volume":"160","author":"Samanta","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0450","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dmcn.12573","article-title":"Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study","volume":"57","author":"Riikonen","year":"2015","journal-title":"Dev Med Child Neurol"},{"issue":"187","key":"10.1016\/j.yebeh.2024.110123_b0455","first-page":"e1","article-title":"Ocular examinations, findings, and toxicity in children taking vigabatrin","volume":"26","author":"Schein","year":"2022","journal-title":"J aapos"},{"key":"10.1016\/j.yebeh.2024.110123_b0460","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WNO.0000000000000609","article-title":"Vigabatrin: lessons learned from the united states experience","volume":"38","author":"Foroozan","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.yebeh.2024.110123_b0465","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1212\/WNL.0000000000001069","article-title":"Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study","volume":"83","author":"Westall","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2024.110123_b0470","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10633-012-9320-7","article-title":"Electroretinographic (ERG) responses in pediatric patients using vigabatrin","volume":"124","author":"Moskowitz","year":"2012","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.yebeh.2024.110123_b0475","first-page":"e45049","article-title":"A case of vigabatrin toxicity mimicking bilateral thalamic infarcts on MRI","volume":"15","author":"Lockard","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.yebeh.2024.110123_b0480","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221138148","article-title":"Vigabatrin-associated brain abnormalities on MRI in tuberous sclerosis complex patients with infantile spasms: are they preventable?","volume":"15","author":"Wan","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2024.110123_b0485","first-page":"7249237","article-title":"Vigabatrin-induced encephalopathy in a 5.5-month-old girl with infantile spasms due to tuberous sclerosis","volume":"2019","author":"Klinaki","year":"2019","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.yebeh.2024.110123_b0490","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/epi4.12652","article-title":"The state of pediatric tuberous sclerosis complex epilepsy care: Results from a national survey","volume":"7","author":"Whitney","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.110123_b0495","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/psp4.12502","article-title":"Model-informed drug development for everolimus dosing selection in pediatric infant patients","volume":"9","author":"Combes","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.yebeh.2024.110123_b0500","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2217\/pgs-2023-0140","article-title":"Retrospective pharmacogenetic study in a cohort of pediatric tuberous sclerosis complex patients using everolimus","volume":"24","author":"Concha","year":"2023","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.yebeh.2024.110123_b0505","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0039-1695786","article-title":"Cannabidiol interacts significantly with everolimus-report of a patient with tuberous sclerosis complex","volume":"50","author":"Wiemer-Kruel","year":"2019","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.yebeh.2024.110123_b0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2019.11.017","article-title":"Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex","volume":"105","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0515","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40263-021-00839-4","article-title":"Efficacy, retention and tolerability of everolimus in patients with tuberous sclerosis complex: a survey-based study on patients' perspectives","volume":"35","author":"Willems","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2024.110123_b0520","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2024.110123_b0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pediatrneurol.2021.03.007","article-title":"Diabetes in individuals with tuberous sclerosis complex treated with mTOR inhibitors","volume":"120","author":"Agricola","year":"2021","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.630378","article-title":"tuberous sclerosis registry to increase disease awareness (TOSCA) post-authorisation safety study of everolimus in patients with tuberous sclerosis complex","volume":"12","author":"Kingswood","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0535","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.12956","article-title":"Consensus panel recommendations for the optimization of EPIDIOLEX\u00ae treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex","author":"Wechsler","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.110123_b0540","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/cpt.3004","article-title":"Assessing liver effects of cannabidiol and valproate alone and in combination using quantitative systems toxicology","volume":"114","author":"Lakhani","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2024.110123_b0545","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.110123_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109159","article-title":"Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex\u00ae (cannabidiol) in patients with refractory epilepsy","volume":"141","author":"Georgieva","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.110123_b0555","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fneur.2020.00829","article-title":"Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study","volume":"11","author":"D'Onofrio","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0560","article-title":"Commentary regarding the results of the PREVeNT and EPISTOP trials","author":"J\u00f3\u017awiak","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0565","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ana.26855","article-title":"Chance bias arising from TSC2 mutation imbalance in the PREVeNT trial","volume":"95","author":"Samanta","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0570","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pediatrneurol.2020.03.008","article-title":"An updated review of tuberous sclerosis complex-associated autism spectrum disorder","volume":"109","author":"Samanta","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100715","article-title":"The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial","volume":"32","author":"Amin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.yebeh.2024.110123_b0580","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pediatrneurol.2022.11.017","article-title":"Stiripentol for drug-resistant epilepsy treatment in tuberous sclerosis complex","volume":"139","author":"Aungaroon","year":"2023","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0585","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Perucca E, Perucca P, Tomson T, White HS. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. Epilepsia 2024.","DOI":"10.1111\/epi.18056"},{"key":"10.1016\/j.yebeh.2024.110123_b0590","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.879451","article-title":"Bumetanide effects on resting-state EEG in tuberous sclerosis complex in relation to clinical outcome: an open-label study","volume":"16","author":"Juarez-Martinez","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.yebeh.2024.110123_b0595","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejpn.2024.01.005","article-title":"Response to updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy","volume":"49","author":"Amin","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0600","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pediatrneurol.2020.03.017","article-title":"Prophylactic antiepileptic treatment in tuberous sclerosis","volume":"110","author":"Choudhury","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0605","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12887-023-04137-4","article-title":"Childhood tuberous sclerosis complex in southern Sweden: a paradigm shift in diagnosis and treatment","volume":"23","author":"Pearsson","year":"2023","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.yebeh.2024.110123_b0610","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/dmcn.15265","article-title":"Prenatal diagnosis and intervention improve developmental outcomes and epilepsy prognosis in children with tuberous sclerosis complex","volume":"64","author":"Wang","year":"2022","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2024.110123_b0615","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s00381-021-05218-4","article-title":"Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report","volume":"37","author":"Cavalheiro","year":"2021","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.yebeh.2024.110123_b0620","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb1703","article-title":"Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin","volume":"7","author":"Cheah","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.yebeh.2024.110123_b0625","doi-asserted-by":"crossref","unstructured":"CADTH Reimbursement Reviews and Recommendations. In: Cannabidiol (Epidiolex): CADTH Reimbursement Recommendation: Indication: As adjunctive therapy for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 2 years of age and older. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024.","DOI":"10.51731\/cjht.2024.886"},{"key":"10.1016\/j.yebeh.2024.110123_b0630","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s41669-024-00474-x","article-title":"A cost-utility analysis of add-on cannabidiol versus usual care alone for the treatment of seizures associated with tuberous sclerosis complex in england and wales","volume":"8","author":"Burke","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.yebeh.2024.110123_b0635","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13023-023-02994-x","article-title":"Treatment guidelines for rare, early-onset conditions associated with epileptic seizures: a literature review on Rett syndrome and tuberous sclerosis complex","volume":"19","author":"Amin","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2024.110123_b0640","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/epi4.12459","article-title":"A survey of the european reference network EpiCARE on clinical practice for selected rare epilepsies","volume":"6","author":"Baumgartner","year":"2021","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2024.110123_b0645","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-023-02677-7","article-title":"Shared decision-making and the caregiver experience in tuberous sclerosis complex: results from a UK survey","volume":"18","author":"Skrobanski","year":"2023","journal-title":"Orphanet J Rare Dis"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024005055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:42:06Z","timestamp":1734612126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024005055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":130,"alternative-id":["S1525505024005055"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110123","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving treatment strategies for early-life seizures in Tuberous Sclerosis Complex: A review and treatment algorithm","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.110123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110123"}}